Literature DB >> 18467103

'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines.

Danielle M Schultz1, Jennifer A Prescher, Stephanie Kidd, Danuta Marona-Lewicka, David E Nichols, Aaron Monte.   

Abstract

Phenylalkylamines that possess conformationally rigidified furanyl moieties in place of alkoxy arene ring substituents have been shown previously to possess the highest affinities and agonist functional potencies at the serotonin 5-HT(2A) receptor among this chemical class. Further, affinity declines when both furanyl rings are expanded to the larger dipyranyl ring system. The present paper reports the synthesis and pharmacological evaluation of a series of 'hybrid' benzofuranyl-benzopyranyl phenylalkylamines to probe further the sizes of the binding pockets within the serotonin 5-HT(2A) agonist binding site. Thus, 4(a-b), 5(a-b), and 6 were prepared as homologs of the parent compound, 8-bromo-1-(2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminopropane 2, and their affinity, functional potency, and intrinsic activity were assessed using cells stably expressing the rat 5-HT(2A) receptor. The behavioral pharmacology of these new analogs was also evaluated in the two-lever drug discrimination paradigm. Although all of the hybrid isomers had similar, nanomolar range receptor affinities, those with the smaller furanyl ring at the arene 2-position (4a-b) displayed a 4- to 15-fold greater functional potency than those with the larger pyranyl ring at that position (5a-b). When the furan ring of the more potent agonist 4b was aromatized to give 6, a receptor affinity similar to the parent difuranyl compound 2 was attained, along with a functional potency equivalent to 2, 4a, and 4b. In drug discrimination experiments using rats trained to discriminate LSD from saline, 4b was more than two times more potent than 5b, with the latter having a potency similar to the classic hallucinogenic amphetamine 1 (DOB).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18467103      PMCID: PMC2601679          DOI: 10.1016/j.bmc.2008.04.030

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  20 in total

1.  1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists.

Authors:  Thomas H McLean; Jason C Parrish; Michael R Braden; Danuta Marona-Lewicka; Alejandra Gallardo-Godoy; David E Nichols
Journal:  J Med Chem       Date:  2006-09-21       Impact factor: 7.446

2.  Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists.

Authors:  Michael R Braden; Jason C Parrish; John C Naylor; David E Nichols
Journal:  Mol Pharmacol       Date:  2006-09-25       Impact factor: 4.436

3.  A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor.

Authors:  M A Parker; D Marona-Lewicka; V L Lucaites; D L Nelson; D E Nichols
Journal:  J Med Chem       Date:  1998-12-17       Impact factor: 7.446

4.  Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists.

Authors:  Jason C Parrish; Michael R Braden; Emily Gundy; David E Nichols
Journal:  J Neurochem       Date:  2005-11-08       Impact factor: 5.372

5.  C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.

Authors:  Thomas H McLean; James J Chambers; Jason C Parrish; Michael R Braden; Danuta Marona-Lewicka; Deborah Kurrasch-Orbaugh; David E Nichols
Journal:  J Med Chem       Date:  2006-07-13       Impact factor: 7.446

Review 6.  Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents.

Authors:  R A Glennon; J A Rosecrans; R Young
Journal:  Med Res Rev       Date:  1983 Jul-Sep       Impact factor: 12.944

7.  Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups.

Authors:  A P Monte; D Marona-Lewicka; M A Parker; D B Wainscott; D L Nelson; D E Nichols
Journal:  J Med Chem       Date:  1996-07-19       Impact factor: 7.446

8.  Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves.

Authors:  Deborah M Kurrasch-Orbaugh; Val J Watts; Eric L Barker; David E Nichols
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

9.  A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor.

Authors:  James J Chambers; David E Nichols
Journal:  J Comput Aided Mol Des       Date:  2002-07       Impact factor: 3.686

10.  Translocation of the 5-alkoxy substituent of 2,5-dialkoxyarylalkylamines to the 6-position: effects on 5-HT(2A/2C) receptor affinity.

Authors:  James J Chambers; Deborah M Kurrasch-Orbaugh; David E Nichols
Journal:  Bioorg Med Chem Lett       Date:  2002-08-05       Impact factor: 2.823

View more
  3 in total

1.  Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.

Authors:  Amy E Moritz; R Benjamin Free; Warren S Weiner; Emmanuel O Akano; Disha Gandhi; Ara Abramyan; Thomas M Keck; Marc Ferrer; Xin Hu; Noel Southall; Joseph Steiner; Jeffrey Aubé; Lei Shi; Kevin J Frankowski; David R Sibley
Journal:  J Med Chem       Date:  2020-05-12       Impact factor: 7.446

2.  Synthesis of 3-selanylbenzo[b]furans promoted by SelectFluor®.

Authors:  Maurício Carpe Diem Ferreira Xavier; Eduardo Martarelo Andia Sandagorda; José Sebastião Santos Neto; Ricardo Frederico Schumacher; Márcio Santos Silva
Journal:  RSC Adv       Date:  2020-04-07       Impact factor: 4.036

3.  Synthesis of Novel Benzodifuranyl; 1,3,5-Triazines; 1,3,5-Oxadiazepines; and Thiazolopyrimidines Derived from Visnaginone and Khellinone as Anti-Inflammatory and Analgesic Agents.

Authors:  Ameen Ali Abu-Hashem; Sami A Al-Hussain; Magdi E A Zaki
Journal:  Molecules       Date:  2020-01-05       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.